1. Home
  2. AUUD vs GRI Comparison

AUUD vs GRI Comparison

Compare AUUD & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Auddia Inc.

AUUD

Auddia Inc.

N/A

Current Price

$1.00

Market Cap

4.1M

Sector

Technology

ML Signal

N/A

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

N/A

Current Price

$0.40

Market Cap

4.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AUUD
GRI
Founded
2012
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1M
4.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
AUUD
GRI
Price
$1.00
$0.40
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$23.00
AVG Volume (30 Days)
75.2K
1.3M
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.84
$0.43
52 Week High
$14.60
$15.64

Technical Indicators

Market Signals
Indicator
AUUD
GRI
Relative Strength Index (RSI) 38.47 20.94
Support Level $1.10 $0.50
Resistance Level $1.25 $2.17
Average True Range (ATR) 0.08 0.16
MACD 0.02 -0.16
Stochastic Oscillator 21.78 0.39

Price Performance

Historical Comparison
AUUD
GRI

About AUUD Auddia Inc.

Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: